1. eRMP
  2. KYMRIAH

KYMRIAH

KYMRIAH®
Indications

Kymriah® is a genetically-modified autologous immunocellular therapy indicated for the treatment of:

  • Paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
  • Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
  • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
KYMRIAH®

Package Insert

HSA Approved RMP – Patient Educational Leaflet HSA Approved RMP – Patient Alert Card

HSA Approved RMP – HCP Training Material HSA Approved RMP – Pharmacy/Cell Lab/Infusion Center Training Material

Rate this content: 
0
No votes yet
FA-11321266, FA-11321263, FA-11321258, FA-11342404
Print
×

Medical Information Request

×

Ask Speakers